| 纯度 | > 90 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | CA13 |
| Uniprot No | Q8N1Q1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-262aa |
| 氨基酸序列 | MSRLSWG YREHNGPIHW KEFFPIADGD QQSPIEIKTK EVKYDSSLRP LSIKYDPSSA KIISNSGHSF NVDFDDTENK SVLRGGPLTG SYRLRQVHLH WGSADDHGSE HIVDGVSYAA ELHVVHWNSD KYPSFVEAAH EPDGLAVLGV FLQIGEPNSQ LQKITDTLDS IKEKGKQTRF TNFDLLSLLP PSWDYWTYPG SLTVPPLLES VTWIVLKQPI NISSQQLAKF RSLLCTAEGE AAAFLVSNHR PPQPLKGRKV RASFH |
| 预测分子量 | 32 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CA13重组蛋白的3篇示例参考文献(注：文献信息为模拟示例，仅供参考格式)：
1. **文献名称**：*Cloning and Expression of Recombinant Human Carbonic Anhydrase XIII in E. coli*
**作者**：Smith A, et al.
**摘要**：该研究成功在大肠杆菌中克隆并表达了重组人CA13蛋白，优化了纯化条件，并通过质谱和酶活性测定验证了其生物活性，为后续功能研究提供了基础。
2. **文献名称**：*Structural Insights into CA XIII: Crystallographic Analysis of a Novel Isoform*
**作者**：Johnson R, et al.
**摘要**：通过X射线晶体学解析了CA13的三维结构，揭示了其活性位点的独特氨基酸组成，并探讨了与其他碳酸酐酶亚型的功能差异。
3. **文献名称**：*Role of CA XIII in Respiratory Physiology: A Knockout Mouse Study*
**作者**：Lee S, et al.
**摘要**：利用CA13基因敲除小鼠模型，发现CA13在肺组织二氧化碳代谢中发挥辅助作用，并可能与慢性呼吸疾病相关。
---
如需真实文献，建议通过PubMed或SciFinder检索关键词“CA13 recombinant protein”或“carbonic anhydrase XIII expression”获取最新研究。
CA13 (Carbonic Anhydrase XIII) is a member of the carbonic anhydrase (CA) family, a group of zinc metalloenzymes that catalyze the reversible hydration of carbon dioxide (CO₂) to bicarbonate (HCO₃⁻) and protons (H⁺). This reaction is critical for maintaining acid-base balance, ion transport, and metabolic processes in various tissues. Among the 15 human CA isoforms, CA13 is a relatively less studied enzyme encoded by the *CA13* gene. It is classified as a secreted protein due to its extracellular localization, though its precise physiological role remains under investigation.
CA13 is expressed in specific tissues, including salivary glands, respiratory epithelium, and the kidney, suggesting potential roles in modulating bicarbonate-rich secretions or regulating local pH environments. Unlike other CA isoforms (e.g., CA II or CA IX), CA13 exhibits distinct structural features, such as a unique N-terminal signal peptide for secretion and variations in active-site residues, which may influence its catalytic efficiency or substrate specificity.
Recombinant CA13 protein is produced using heterologous expression systems (e.g., *E. coli* or mammalian cells*) to enable functional and structural studies. Its recombinant form allows researchers to explore its enzymatic kinetics, inhibitor interactions, and potential biomedical applications. For instance, CA13 has been implicated in diseases like cancers and metabolic disorders, where aberrant CA activity may contribute to pathogenesis. Additionally, CA13 inhibitors could serve as therapeutic agents or diagnostic tools, though further validation is required.
The development of recombinant CA13 also aids in elucidating its role in physiological processes, such as mucosal defense or fluid homeostasis, and provides a platform for comparative studies with other CA isoforms. Despite its lower catalytic activity compared to dominant isoforms like CA II, CA13’s unique tissue distribution and secretory nature highlight its specialized biological significance, warranting deeper exploration into its molecular mechanisms and therapeutic potential.
在生物科技领域，蛋白研发与生产是前沿探索的关键支撑。艾普蒂作为行业内的创新者，凭借自身卓越的研发实力，每年能成功研发 1000 多种全新蛋白，在重组蛋白领域不断突破。 在重组蛋白生产过程中，艾普蒂积累了丰富且成熟的经验。从结构复杂的跨膜蛋白，到具有特定催化功能的酶、参与信号传导的激酶，再到用于免疫研究的病毒抗原，艾普蒂都能实现高效且稳定的生产。 这一成就离不开艾普蒂强大的技术平台。我们构建了多元化的重组蛋白表达系统，昆虫细胞、哺乳动物细胞以及原核蛋白表达系统协同运作。不同的表达系统各有优势，能够满足不同客户对重组蛋白的活性、产量、成本等多样化的需求，从而提供高品质、低成本的活性重组蛋白。 艾普蒂提供的不只是产品，更是从源头到终端的一站式解决方案。从最初的基因合成，精准地构建出符合要求的基因序列，到载体构建，为蛋白表达创造适宜的环境，再到蛋白质表达和纯化，每一个环节都严格把控。我们充分尊重客户的个性化需求，在表达 / 纯化标签的选择、表达宿主的确定等方面，为客户量身定制专属方案。 同时，艾普蒂还配备了多种纯化体系，能够应对不同特性蛋白的纯化需求。这种灵活性和专业性，极大地提高了蛋白表达和纯化的成功率，让客户的研究项目得以顺利推进，在生物科技的探索道路上助力每一位科研工作者迈向成功。
艾普蒂生物自主研发并建立综合性重组蛋白生产和抗体开发技术平台，包括： 哺乳动物细胞表达平台：利用哺乳动物细胞精准修饰蛋白，产出与天然蛋白相似的重组蛋白，用于药物研发、细胞治疗等。 杂交瘤开发平台：通过细胞融合筛选出稳定分泌单克隆抗体的杂交瘤细胞株，优化后的技术让抗体亲和力与特异性更高，应用于疾病诊断、免疫治疗等领域。 单 B 细胞筛选平台：FACS 用荧光标记和流式细胞仪快速分选特定 B 细胞；Beacon® 基于微流控技术，单细胞水平捕获、分析 B 细胞，挖掘抗体多样性，缩短开发周期。 凭借这些平台，艾普蒂生物为客户提供优质试剂和专业 CRO 技术服务，推动生物科技发展。
艾普蒂生物在重组蛋白和天然蛋白开发领域经验十分丰富，拥有超过 2 万种重组蛋白的开发案例。在四大重组蛋白表达平台的运用上，艾普蒂生物不仅经验老到，还积累了详实的成功案例。针对客户的工业化生产需求，我们能够定制并优化实验方案。通过小试探索、工艺放大以及条件优化等环节，对重组蛋白基因序列进行优化，全面探索多种条件，精准找出最契合客户需求的生产方法。 此外，公司还配备了自有下游验证平台，可对重组蛋白展开系统的质量检测与性能测试，涵盖蛋白互作检测、活性验证、内毒素验证等，全方位保障产品质量。 卡梅德生物同样重视蛋白工艺开发，确保生产出的蛋白质具备所需的纯度、稳定性与生物活性，这对于保障药物的安全性和有效性起着关键作用 ，与艾普蒂生物共同推动着行业的发展。
×
